Completed
PHASE3
INTERVENTIONAL
NCT00628758
A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The primary objective is to compare the efficacy of Symbicort Single inhaler Therapy with treatment according to conventional best practice in adult patients with persistent asthma.
Detailed Description
A secondary objective is to collect safety data for treatment wtih Symbicort Single inhaler Therapy in adult patients with persistent asthma.
Interventions
Name:
Symbicort TBH - Turbuhaler
Type:
DRUG
Description:
Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed)
Name:
beta-II-agonist, inhale steroid
Type:
DRUG
Description:
Salbulin inh. 200-400 dosage 100 microgram (mcg)/dosage Salbutamol Sustained Release(SR)capsule 4 mg/8 mg Salbutol tablet (tb) 2 mg Salbutol forte syrup 2 mg/5 ml Ventolin tb, syrup, intravenous(IV),5mgx10 ampule(amp) Ventolin inhaler (inh) 200 dosage, 100 mcg/dosage Ventolin nebul 2.5 mg Volmax tb 4 mg/8 mg Vent-o-sal inh 100 mcg/200 dosage Combivent inh 100 mcg/dosage Combivent neb 2.5 mg/dosage Bricanyl tb 2.5 mg Bricanyl durules ret tb 5 mg Bricanyl syrup 30mg Bricanyl inhaler 0.25 mg/dosage, 400 dosage Bricanyl turbuhaler 0.5 mg/dosage, 200dosage
Primary Outcomes
Measure:
Time to First Severe Asthma Exacerbation
TimeFrame:
26 weeks
Description:
Time to severe exacerbation among patients
Trial Information
NCT ID
NCT00628758
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
AstraZeneca
Last Updated
December 15, 2025